Renal cell carcinoma

Current Opinion in Oncology

Volumn 21, Issue 3, 2009, Pages 266-271

  Garcia, Jorge A ^a   Cowey, C Lance ^b   Godley, Paul A ^b,c  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Antiangiogenesis; Mammalian target of rapamycin; Multitargeted kinase inhibitor; Renal cell carcinoma; Von Hippel Lindau

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; CARBONATE DEHYDRATASE IX; EVEROLIMUS; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VON HIPPEL LINDAU PROTEIN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE; TUMOR MARKER; VASCULOTROPIN A;

ADVANCED CANCER; ANOREXIA; ASTHENIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG ERUPTION; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; FATIGUE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LOSS OF FUNCTION MUTATION; NEPHRECTOMY; OUTCOME ASSESSMENT; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEX DIFFERENCE; STOMATITIS; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; DISEASE COURSE; DRUG ANTAGONISM; DRUG EFFECT; KIDNEY TUMOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; HUMANS; KIDNEY NEOPLASMS; PROTEIN KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67650364194     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32832a05c8     Document Type: Review

References (40)

1. American Cancer Society. Cancer Facts and Figures 2008. Atlanta: American Cancer Society; 2008.
2. Stafford HS, Saltzstein SL, Shimasaki S, et al. Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. J Urol 2008; 179:1704-1708.
3. Hu J, Chen Y, Mao Y, et al. Alcohol drinking and renal cell carcinoma in Canadian men and women. Cancer Detect Prev 2008; 32:7-14.
4. Pelucchi C, Galeone C, Montella M, et al. Alcohol consumption and renal cell cancer risk intwo Italiancase-control studies. Ann Oncol 2008;19:1003-1008. Data from two case-control studies performed in Italy were used to confirm a protective effect of alcohol consumption from renal cell carcinoma. The study used 1115 cases and 2582 hospitalized controls. The ORs were 0.85 (95% CI 0.71-1.02) for wine, 0.84 (95% CI 0.68-1.03) for beer and 0.86 (95% CI 0.70-1.05) for spirits consumption, as compared with abstainers.
5. Lee JE, Hunter DJ, Spiegelman D, et al. Alcohol intake and renal cell cancer in a pooled analysis of 12 prospective studies. J Natl Cancer Inst 2007; 99:801-810. Definitive pooled analysis consisting of 13 prospective studies of 530 469 women and 244 483 men over a 7-20 year follow-up period. No significant dietary risk factors for renal cell carcinoma were demonstrated after adjusting for BMI, and fruit, vegetable and alcohol intake.
6. Moore SC, Chow WH, Schatzkin A, et al. Physical activity during adulthood and adolescence in relation to renal cell cancer. Am J Epidemiol 2008; 168:149-157.
7. Khurana V, Caldito G, Ankem M. Statins might reduce risk of renal cell carcinoma in humans: case-control study of 500,000 veterans. Urology 2008; 71:118-122.
8. Bidoli E, Talamini R, Zucchetto A, et al. Macronutrients, fatty acids, cholesterol and renal cell cancer risk. Int J Cancer 2008; 122:2586-2589.
9. Lee JE, Spiegelman D, Hunter DJ, et al. Fat, protein, and meat consumption and renal cell cancer risk: a pooled analysis of 13 prospective studies. J Natl Cancer Inst 2008; 100:1695-1706.
10. Weikert S, Boeing H, Pischon T, et al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol 2008; 167:438-446.
11. Pascual D, Borque A. Epidemiology of kidney cancer. Adv Urol 2008:782381.
12. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17:2530-2540.
13. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23:832-841.
14. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007; 110:543-550.
15. Motzer RJ, Bukowski RM, Figlin RA, et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 2008; 113:1552-1558. An updated nomogram for predicting survival for patients with metastatic RCC receiving sunitinib-based therapy.
16. Choueiri TK, Vaziri SA, Jaeger E, et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008; 180:860-865; discussion 5-6. An evaluation of VHL gene status as a potential prognostic marker in patients treated with VEGF targeted therapies.
17. Sandlund J, Oosterwijk E, Grankvist K, et al. Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int 2007; 100:556-560.
18. Leibovich BC, Sheinin Y, Lohse CM, et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol 2007; 25:4757-4764.
19. Li G, Feng G, Gentil-Perret A, et al. Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. J Urol 2008; 180:510-513; discussion 3-4.
20. Golshayan AR, Brick AJ, Choueiri TK. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies. Future Oncol 2008; 4:85-92.
21. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008; 26:3743-3748. A correlative study exploring VEGF and soluble VEGF receptor levels in patients treated with sunitinib after progression on bevacizumab.
22. Figlin RA, Hutson TE, Tomczak P, et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol (Meeting Abstracts) 2008; 26 (15):5024-. This study discusses the overall survival seen in the phase III sunitinib trial
23. Motzer RJ, Michaelson MD, Rosenberg J, et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007; 178:1883-1887.
24. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-2281.
25. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, doubleblind phase III trial. Lancet 2007; 370:2103-2111. This study establishes bevacizumab/INF as a standard of care for first line treatment of patients with metastatic renal cell carcinoma.
26. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26:5422-5428. This study establishes bevacizumab/INF as a standard of care for first line treatment of patients with metastatic renal cell carcinoma.
27. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renalcell carcinoma. N Engl J Med 2007; 356:125-134.
28. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372:449-456. This study demonstrates the clinical activity on everolimus as a sequential treatment in advanced RCC.
29. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124. This study establishes sunitinib as the standard of care for first line treatment of most patients with metastatic renal cell carcinoma.
30. Hutson TE, Davis ID, Machiels JH, et al. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multikinase angiogenesis inhibitor. J Clin Oncol (Meeting Abstracts) 2008; 26 (15-suppl):5046.
31. Tamaskar I, Garcia JA, Elson P, et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008; 179:81-86; discussion 6.
32. Sablin MP, Bouaita L, Balleyguier C, et al. Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients. J Clin Oncol (Meeting Abstracts) 2007; 25 (18-suppl):5038.
33. Rini BI, Wilding GT, Hudes G, et al. Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. J Clin Oncol (Meeting Abstracts) 2007; 25 (18-suppl):5032.
34. Shepard DR, Rini BI, Garcia JA, et al. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J Clin Oncol (Meeting Abstracts) 2008; 26 (15-suppl):5123.
35. Ryan CW, Goldman BH, Lara PN Jr, et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 2007; 25:3296-3301.
36. Gollob JA, Rathmell WK, Richmond TM, et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 2007; 25:3288-3295.
37. Escudier B, Lassau N, Angevin E, et al. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 2007; 13:1801-1809.
38. Fischer P, Patel P, Carducci MA, et al. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. J Clin Oncol (Meeting Abstracts) 2008; 26 (15-suppl):16020.
39. Feldman DR, Ginsberg MS, Baum M, et al. Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol (Meeting Abstracts) 2008; 26 (15-suppl):5100.
40. Cooney MM, Garcia JA, Elson P, et al. Sunitinib and bevacizumab in advanced solid tumors: a phase I trial. J Clin Oncol Meeting Abstracts 2008; 26 (15-suppl):3530.